ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly cardiovascular therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2018] ($M)
Form 10-K Segment & Disaggregated Revenue Note (legacy Cardiovascular grouping)
Latest, FY2017
2,871
Period ended Dec 31, 2017
Change on a year earlier
-11.0%
3,225 in FY2016
History
7 years
Since FY2011
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cardiovascular therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2018] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2017 | Dec 31, 2017 | 2,871 | -11.0% | Form 10-K (filed 2018-02-20) ↗ |
| FY2016 | Dec 31, 2016 | 3,225 | +5.1% | Form 10-K (filed 2018-02-20) ↗ |
| FY2015 | Dec 31, 2015 | 3,068 | +0.5% | Form 10-K (filed 2016-02-19) ↗ |
| FY2014 | Dec 31, 2014 | 3,054 | +4.5% | Form 10-K (filed 2015-02-19) ↗ |
| FY2013 | Dec 31, 2013 | 2,923 | +11.0% | Form 10-K (filed 2014-02-19) ↗ |
| FY2012 | Dec 31, 2012 | 2,633 | +5.9% | Form 10-K (filed 2014-02-19) ↗ |
| FY2011 | Dec 31, 2011 | 2,486 | – | Form 10-K (filed 2014-02-19) ↗ |
Breakdown
What makes up cardiovascular therapeutic area — worldwide revenue ($m) [legacy grouping through fy2018]
Cite this data
StockData. (2026). Eli Lilly Cardiovascular therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2018] ($M), annual FY2011–FY2017 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_cardiovascular_ww_legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.